Education
About Us
Working with TipRanks
Follow Us
Neuropace, Inc. (NPCE)
:NPCE
Earnings Data
Report Date
Mar 10, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.18Last Year’s EPS
-0.18Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, positive adjusted EBITDA, and increased guidance. There were challenges, including the winding down of the DIXI product line and extended timelines for pediatric indication, but these were outweighed by positive developments and strategic progress.Company Guidance
Record Revenue and Growth
NeuroPace achieved a total revenue of $27.4 million in Q3 2025, marking a 30% year-over-year growth compared to $21.1 million in the prior year quarter. This was driven by RNS initial implants, with RNS revenue at $22.6 million, representing a 31% year-over-year growth.
Positive Adjusted EBITDA
NeuroPace generated positive adjusted EBITDA for the first time in its history, reflecting strong scalability and disciplined expense management.
Increased Revenue and Gross Margin Guidance
Full year revenue guidance was raised to $97 million to $98 million, up from $94 million to $98 million, reflecting a 21% to 23% year-over-year growth. Gross margin guidance was also increased to 76% to 77%, up from 75% to 76%.
FDA Submission Progress
Progress was made with the NAUTILUS study and the pediatric indication. The PMA supplement for NAUTILUS is on track to be submitted before year-end.
Strong RNS System Performance
RNS System gross margin remained above 80%, benefiting from improved manufacturing efficiency and favorable pricing.
Peer Recognition
The RNS System was featured in the Journal of Clinical Neurophysiology, highlighting its unique closed-loop stimulation capabilities.
NPCE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NPCE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 04, 2025 | $9.40 | $12.98 | +38.09% |
Aug 12, 2025 | $9.13 | $9.32 | +2.08% |
May 13, 2025 | $12.95 | $15.60 | +20.46% |
Mar 04, 2025 | $11.92 | $11.63 | -2.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Neuropace, Inc. (NPCE) report earnings?
Neuropace, Inc. (NPCE) is schdueled to report earning on Mar 10, 2026, After Close (Confirmed).
What is Neuropace, Inc. (NPCE) earnings time?
Neuropace, Inc. (NPCE) earnings time is at Mar 10, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NPCE EPS forecast?
NPCE EPS forecast for the fiscal quarter 2025 (Q4) is -0.18.